Product Specifications
| Markets: |
North America,South America,Eastern Europe,Southeast Asia,Africa,Oceania,Mid East,Eastern Asia,Western Europe |
Product Description
Vitamin K1 Injection is indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity.
Vitamin K1 Injection is indicated in:
--anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives;
--prophylaxis and therapy of hemorrhagic disease of the newborn;
--hypoprothrombinemia due to antibacterial therapy;
--hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e. G., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis;
--other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin K metabolism, e. G., salicylates.
Tianjin Pharmaceutical Group Xinzheng Co., Ltd, located at Xizheng, Henan province, China is a subsidiary pharmaceutical company of Tianjin Pharmaceutical Group. There is the biggest manufacturer of small volume injection in China.
So far, we produce various finished dosage forms such as:
Tablets/capsules, Granules, oinement, cream, raw materials, oral solution, injection, which is around 150 kinds of drugs. Our company is also a hi-tech enterprise awarded the state enterprise with technical assessment center.
Depending on the advanced manufacturing equipments and high quality products with various kinds of drugs, lower prices, good reputation and good marketing condition, service idea, stronger capital foundation, duty to society make the company a sound business relationship with government purchasing organization, Medical sector agents and drugs store step by step. A nationwide marketing network was established in a short period.
